The Texas ivermectin bill, introduced in the Texas House of Representatives, is reigniting debate over a drug that became a flashpoint during the COVID-19 pandemic. House Bill 3175, some are calling the Texas ivermectin bill, filed by Representative Virdell and now referred to the House Public Health Committee, would authorize pharmacists in Texas to dispense ivermectin without a prescription under a statewide standing order. The bill outlines specific guidance for pharmacists, who would be required to follow protocols issued by the Texas Department of State Health Services and provide usage instructions to patients. Additionally, pharmacists dispensing the drug would be shielded from legal liability, except in cases of gross negligence or willful misconduct.
During the pandemic, ivermectin was the subject of considerable controversy. While it has long been approved by the FDA to treat parasitic infections in humans and animals, its promotion as a potential COVID-19 treatment drew skepticism from much of the medical establishment and widespread criticism from media outlets. Despite anecdotal support and some limited studies suggesting potential antiviral properties, major public health organizations—including the FDA and CDC—warned against its use for COVID-19, citing insufficient evidence and potential risks when used inappropriately. Retail availability was curtailed, and in many cases, patients were unable to obtain prescriptions even from willing physicians. Pharmacists often declined to fill ivermectin prescriptions, citing regulatory uncertainty and concerns over professional discipline.
If passed, HB 3175 would change the accessibility of ivermectin in Texas significantly. The bill empowers the state health commissioner to create a standardized system for pharmacists to dispense the drug directly to consumers. It includes a requirement for an annual report on the number of doses dispensed, suggesting the legislature is interested in monitoring usage trends. Furthermore, the Texas State Board of Pharmacy and the executive commissioner of health services would be authorized to adopt rules for implementing the bill.
Proponents argue that the legislation restores access to a drug that was difficult to obtain during a critical public health emergency. They point to the demand during the pandemic and the frustration from patients who believed ivermectin could help but were unable to access it due to regulatory and institutional roadblocks. Opponents, however, may raise concerns that making the drug available without a prescription could encourage misuse or undermine trust in evidence-based treatments, especially if patients view it as an alternative to vaccines or approved antiviral therapies.
The bill’s passage would mark a notable shift in how ivermectin is treated under Texas law, potentially setting a precedent for broader access to off-label medications during public health crises. It would also reflect a growing movement among some lawmakers to challenge federal health guidance and expand medical autonomy at the state level. If it receives a two-thirds majority vote in both chambers, it would take effect immediately; otherwise, the law would become effective on September 1, 2025.
As of March 20, 2025, House Bill 3175 has been referred to the House Public Health Committee following its initial reading. In the Texas legislative process, a bill must pass out of committee before it can be debated and voted on by the full House. If approved, it then proceeds to the Senate for a similar process. Should both chambers pass the bill, it would be sent to the governor for signature into law. Supporters of the legislation who wish to see it move forward can contact members of the Public Health Committee to express their support, submit public comments, or attend hearings where testimony on the bill may be heard. Staying informed through the Texas Legislature’s official website and engaging with local representatives are effective ways to participate in the legislative process.
